Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ibritumomab Tiuxetan · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Rituximab | DRUG | - |
| CHOP | DRUG | - |
| CVP | DRUG | - |
| Ibritumomab Tiuxetan | DRUG | - |
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Histologic documentation of follicular center, B-cell lymphoma * Early stage lymphoma (stages I or II) relapsed after radiation therapy alone * No previous chemotherapy or monoclonal antibody therapy * Measur...
Ibritumomab Tiuxetan is used for the treatment of Non-Hodgkin's Lymphoma. It is being developed by Biogen Inc. (NASDAQ: BIIB) and is currently in Phase 2 clinical development. The drug is being studied in patients with low grade follicular Non-Hodgkin's Lymphoma.
Ibritumomab Tiuxetan is being developed by Biogen Inc., which is publicly traded under the ticker symbol BIIB on the NASDAQ. The company is conducting clinical trials to evaluate the drug for the treatment of Non-Hodgkin's Lymphoma.
Ibritumomab Tiuxetan is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of Non-Hodgkin's Lymphoma. The drug is not approved and is still undergoing clinical trials to evaluate its safety and efficacy.
Ibritumomab Tiuxetan has one completed clinical trial, NCT00193440, which was a Phase 2 study titled 'Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma'. The trial enrolled 40 patients with Non-Hodgkin's Lymphoma.
Ibritumomab Tiuxetan is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of Non-Hodgkin's Lymphoma. The drug has completed one clinical trial but has not yet received regulatory approval.